Top in GI: Outpatient appendicitis management; promising treatment candidate for NASH
A recent study showed that outpatient antibiotic management was safe compared with in-hospital care for patients with acute appendicitis.
Researchers reported that patients who received outpatient antibiotic management did not have a significantly greater risk for complications or appendectomy. It was the top story in gastroenterology last week.
The second top story was about new data demonstrating the safety and tolerability of resmetirom (Madrigal Pharmaceuticals) among patients with nonalcoholic steatohepatitis (NASH). Stephen Harrison, MD, the medical director for Pinnacle Clinical Research in San Antonio, said that resmetirom has potential to become the first medication approved for the condition.
Read these and more top stories in gastroenterology below:
Outpatient antibiotic management safe for select adults with acute appendicitis
Outpatient antibiotic management was safe compared with in-hospital care, with no greater risk for complications or appendectomy, in a subgroup of patients with acute appendicitis, according to research. Read more.
Resmetirom ‘has potential to be first medication approved’ for patients with NASH
Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with NASH, according to late-breaking research presented at the International Liver Congress. Read more.
VIDEO: Stelara can safely be used long-term to benefit patients with UC, Crohn’s
In a Healio video exclusive, Remo Panaccione, MD, discusses results from long-term, pooled analyses of adult patients treated with Stelara (ustekinumab, Janssen) for inflammatory bowel disease. Watch video.
HBV-listed death rates surpass national average in coastal, Appalachian states
Individuals born in the United States made up nearly two-thirds of all hepatitis B-listed deaths, with death rates exceeding the national average in 13 states, according to research published in JAMA Network Open. Read more.
VIDEO: Terns Pharma ‘builds upon pipeline’ of NASH, obesity research
In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis. Watch video.